Latest news with #DSRCT
Yahoo
10-03-2025
- Entertainment
- Yahoo
Kate Middleton pays tribute to late teen with cancer after fulfilling her ‘bucket list' dream
Catherine, Princess of Wales, is celebrating the life of British teen Liz Hatton, who recently died after being diagnosed with a fast-progressing and rare form of cancer. Hatton was diagnosed with desmoplastic small round cell tumors in January 2024 when she was 16, British outlet Sky News reported. Hatton's mother, Vicky Roboyna, told the outlet that doctors informed her daughter at the time that she only had about six months to three years to live. Hatton, a young photographer, decided to create a 'bucket list' of events and images she wanted to snap before her death. The teen told BBC Radio 4 that one of the items on her list was 'photographing a royal.' In October 2024, she checked off that goal. The official X account for the Prince and Princess of Wales shared a photo of Hatton hugging the former Kate Middleton. The account included another snap of Hatton posing with her family beside Prince William and his wife at Windsor Castle. 'A pleasure to meet with Liz at Windsor today,' the Prince and Princess of Wales tweeted. 'A talented young photographer whose creativity and strength has inspired us both. Thank you for sharing your photos and story with us.' Hatton also uploaded pictures she took from the special day on Instagram. 'I was absolutely honoured to be invited to Windsor Castle the other day, where I had the pleasure of not only photographing the events but also meeting the Prince and Princess with my family alongside me. I could not be more thankful to everyone involved, as you were all so kind, welcoming and supportive,' she captioned a series of snaps. 'Thank you all, and I can only hope that my photos do the day as much justice as possible,' she continued, sharing a second set of photos, as well. About a month later, Hatton's family announced on Instagram that she had died at the age of 17. 'Our incredible daughter Liz died in the early hours of yesterday morning,' her family shared in a Nov. 28, 2024 statement, in part. 'She remained determined to the last. Even the day before she was still making plans. We are so very proud of the kindness, empathy and courage she has shown in the last year. She was not only a phenomenal photographer, she was the best human, and the most wonderful daughter and big sister we could ever have asked for.' Desmoplastic small round cell tumors, or DSRCT, refers to tumors that usually grow in the abdomen or pelvic area, according to the National Cancer Institute. The tumors develop in the connective tissue of the body, like fat, muscles, tendons, lymph and blood vessels and nerves. The National Cancer Institute describes DSRCT as 'very rare' and reports that just 200 cases of the cancer have been recorded since 1989. In honor of International Women's Day on March 8, the Princess of Wales, who was diagnosed with cancer in March 2024, paid tribute to Hatton's legacy on X by including her among 'the brilliant women who have inspired us over the last 12 (months).' She retweeted the post with Hatton from October and said, 'Celebrating the strength and creativity of Liz and Vicky Hatton. It was an honour meeting them both in Windsor in October.' Kate added, 'Liz's memory (lives) on in Vicky's unwavering resilience. Thank you for such a moving moment.' The Princess of Wales announced in January that her cancer is in remission. She shared the news in a statement on Instagram beside a photo of her visiting a cancer patient at the Royal Marsden Hospital, where the royal was also treated and now holds the title of joint patron. 'It is a relief to now be in remission and I remain focussed on recovery. As anyone who has experienced a cancer diagnosis will know, it takes time to adjust to a new normal,' Kate said at the time. 'I am however looking forward to a fulfilling year ahead. There is much to look forward to. Thank you to everyone for your continued support.' This article was originally published on
Associated Press
04-03-2025
- Business
- Associated Press
Lirum Therapeutics Presents Positive Data on LX-101 at the 2025 ESMO Targeted Anticancer Therapies Congress; Highlighting LX-101's Promise in IGF-1R Prominent Cancers
New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. ('Lirum'), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the presentation of additional positive data on LX-101 at the 2025 ESMO Targeted Anticancer Therapies Congress (TAT) in Paris, France. LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), was selected for two presentations at this year's TAT conference. The first presentation, co-authored with investigators from the MD Anderson Cancer Center, showcases LX-101's strong in vivo activity in Ewing sarcoma as well as its potency in in vitro models of both Ewing sarcoma and desmoplastic small round cell tumor (DSRCT). These cancers have strong ties to IGF-1R, including DNA-level gene fusions that affect this signaling pathway. The second presentation highlights LX-101's broad potency against a host of IGF-1R-expressing cell lines from a number of additional adult cancers including lung, esophageal and stomach cancers, which represent large market opportunities. These presentations underscore LX-101's potent activity and promise in both pediatric and adult cancers with well-established ties to the IGF-1R pathway. The presentations are entitled: LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Anti-Tumor Activity in Ewing Sarcoma Animal Models and Desmoplastic Small Round Cell Tumors. LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Preclinical Anti-Tumor Activity Against Multiple Cancer Types with Elevated IGF-1R Expression. Both presentations are available on the Lirum website ( under the Investors and Media tab. Given these promising results, new clinical trials with LX-101 are planned in pediatric indications that carry strong ties to the IGF-1/IGF-1R pathway, including Ewing Sarcoma, DSRCT, rhabdomyosarcoma, and GIST. In addition, Lirum is planning trials in adult patients with cancer types that are naturally enriched for IGF-1R, including certain head and neck indications and others. In parallel, Lirum is also focused on developing LX-101 in thyroid eye disease (TED), where IGF-1R has been clinically and commercially validated. About Lirum Therapeutics, Inc. Lirum is an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways and commercial opportunities. Lirum's lead candidate, LX-101, is a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R) with a differentiated mechanism of action. Lirum is developing LX-101 in oncology and autoimmune indications, including thyroid eye disease (TED). For more information on Lirum, please visit Forward Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Lirum's current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the ability of Lirum to successfully develop its product candidates, including obtaining positive results from planned clinical trials, 2) expectations for the clinical development, manufacturing, regulatory approval and commercialization of our product candidates or other products we may acquire or in-license(3) expectations for incurring capital expenditures and generating revenue, 4) estimates of the sufficiency of our existing cash and cash equivalents and investments to finance operations, 5) changes in applicable laws or regulations; (6) the possibility that Lirum may be adversely affected by other economic, business, and/or competitive factors; (7) the impact of health epidemics, including the COVID-19 pandemic, on Lirum's business and the actions Lirum may take in response thereto; and (8) other risks and uncertainties indicated from time to time. There may be additional risks that Lirum considers immaterial or which are unknown. Any forward-looking statement made by us in this press release is based only on information currently available to Lirum and speaks only as of the date on which it is made. Lirum undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law. Also, the information found on our website is not incorporated by reference into this press release and is included for reference purposes only. Company contact: Matt Hoberman Lirum Therapeutics, Inc. 1270 Ave of the Americas, 7th Floor New York, NY 10020
Yahoo
04-03-2025
- Business
- Yahoo
Lirum Therapeutics Presents Positive Data on LX-101 at the 2025 ESMO Targeted Anticancer Therapies Congress; Highlighting LX-101's Promise in IGF-1R Prominent Cancers
New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. ('Lirum'), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the presentation of additional positive data on LX-101 at the 2025 ESMO Targeted Anticancer Therapies Congress (TAT) in Paris, France. LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), was selected for two presentations at this year's TAT conference. The first presentation, co-authored with investigators from the MD Anderson Cancer Center, showcases LX-101's strong in vivo activity in Ewing sarcoma as well as its potency in in vitro models of both Ewing sarcoma and desmoplastic small round cell tumor (DSRCT). These cancers have strong ties to IGF-1R, including DNA-level gene fusions that affect this signaling pathway. The second presentation highlights LX-101's broad potency against a host of IGF-1R-expressing cell lines from a number of additional adult cancers including lung, esophageal and stomach cancers, which represent large market opportunities. These presentations underscore LX-101's potent activity and promise in both pediatric and adult cancers with well-established ties to the IGF-1R pathway. The presentations are entitled: LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Anti-Tumor Activity in Ewing Sarcoma Animal Models and Desmoplastic Small Round Cell Tumors. LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Preclinical Anti-Tumor Activity Against Multiple Cancer Types with Elevated IGF-1R Expression. Both presentations are available on the Lirum website ( under the Investors and Media tab. Given these promising results, new clinical trials with LX-101 are planned in pediatric indications that carry strong ties to the IGF-1/IGF-1R pathway, including Ewing Sarcoma, DSRCT, rhabdomyosarcoma, and GIST. In addition, Lirum is planning trials in adult patients with cancer types that are naturally enriched for IGF-1R, including certain head and neck indications and others. In parallel, Lirum is also focused on developing LX-101 in thyroid eye disease (TED), where IGF-1R has been clinically and commercially validated. About Lirum Therapeutics, is an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways and commercial opportunities. Lirum's lead candidate, LX-101, is a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R) with a differentiated mechanism of action. Lirum is developing LX-101 in oncology and autoimmune indications, including thyroid eye disease (TED). For more information on Lirum, please visit Forward Looking StatementsThis press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Lirum's current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the ability of Lirum to successfully develop its product candidates, including obtaining positive results from planned clinical trials, 2) expectations for the clinical development, manufacturing, regulatory approval and commercialization of our product candidates or other products we may acquire or in-license(3) expectations for incurring capital expenditures and generating revenue, 4) estimates of the sufficiency of our existing cash and cash equivalents and investments to finance operations, 5) changes in applicable laws or regulations; (6) the possibility that Lirum may be adversely affected by other economic, business, and/or competitive factors; (7) the impact of health epidemics, including the COVID-19 pandemic, on Lirum's business and the actions Lirum may take in response thereto; and (8) other risks and uncertainties indicated from time to time. There may be additional risks that Lirum considers immaterial or which are unknown. Any forward-looking statement made by us in this press release is based only on information currently available to Lirum and speaks only as of the date on which it is made. Lirum undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law. Also, the information found on our website is not incorporated by reference into this press release and is included for reference purposes only. Company contact: Matt HobermanInvestor RelationsIR@ Phone: (646) 389-6015 Lirum Therapeutics, Inc.1270 Ave of the Americas, 7th FloorNew York, NY 10020 Sign in to access your portfolio
